Literature DB >> 12208500

Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells.

Delphine Meisse1, Mark Van de Casteele, Christophe Beauloye, Isabelle Hainault, Benjamin A Kefas, Mark H Rider, Fabienne Foufelle, Louis Hue.   

Abstract

The aim of this work was to study the effect of a sustained activation of AMP-activated protein kinase (AMPK) on liver cell survival. AMPK activation was achieved by incubating FTO2B cells with AICA-riboside, which is transformed into ZMP, an AMP analogue, or by adenoviral transfection of hepatocytes with a constitutively active form of AMPK. Prolonged AMPK activation triggered apoptosis and activated c-Jun N-terminal kinase (JNK) and caspase-3. Experiments with iodotubercidin, dicoumarol and z-VAD-fmk, which inhibited AMPK, JNK and caspase activation, respectively, supported the notion that prolonged AMPK activation in liver cells induces apoptosis through an activation pathway that involves JNK and caspase-3.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208500     DOI: 10.1016/s0014-5793(02)03110-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  52 in total

1.  AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3.

Authors:  Taj D King; Ling Song; Richard S Jope
Journal:  Biochem Pharmacol       Date:  2006-03-10       Impact factor: 5.858

2.  The effect of dehydroleucodine in adipocyte differentiation.

Authors:  Adriana Galvis; Adriana Marcano; Chad Stefancin; Nicole Villaverde; Horacio A Priestap; Carlos E Tonn; Luis A Lopez; Manuel A Barbieri
Journal:  Eur J Pharmacol       Date:  2011-09-19       Impact factor: 4.432

3.  Two-step activation of FOXO3 by AMPK generates a coherent feed-forward loop determining excitotoxic cell fate.

Authors:  D Davila; N M C Connolly; H Bonner; P Weisová; H Dussmann; C G Concannon; H J Huber; J H M Prehn
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

4.  Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases.

Authors:  Michela Capano; Martin Crompton
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

5.  AMP-activated protein kinase is a key intermediary in GnRH-stimulated LHβ gene transcription.

Authors:  Josefa Andrade; Jessica Quinn; Richad Z Becker; Margaret A Shupnik
Journal:  Mol Endocrinol       Date:  2013-03-21

Review 6.  AMPK inhibition in health and disease.

Authors:  Benoit Viollet; Sandrine Horman; Jocelyne Leclerc; Louise Lantier; Marc Foretz; Marc Billaud; Shailendra Giri; Fabrizio Andreelli
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-08       Impact factor: 8.250

Review 7.  Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.

Authors:  Farzad Masoudkabir; Nizal Sarrafzadegan; Carolyn Gotay; Andrew Ignaszewski; Andrew D Krahn; Margot K Davis; Christopher Franco; Arya Mani
Journal:  Atherosclerosis       Date:  2017-06-02       Impact factor: 5.162

8.  5-ALA mediated photodynamic therapy induces autophagic cell death via AMP-activated protein kinase.

Authors:  Hong-Tai Ji; Li-Ting Chien; Yu-Hsin Lin; Hsiung-Fei Chien; Chin-Tin Chen
Journal:  Mol Cancer       Date:  2010-04-28       Impact factor: 27.401

9.  AMP kinase-mediated activation of the BH3-only protein Bim couples energy depletion to stress-induced apoptosis.

Authors:  Caoimhín G Concannon; Liam P Tuffy; Petronela Weisová; Helena P Bonner; David Dávila; Caroline Bonner; Marc C Devocelle; Andreas Strasser; Manus W Ward; Jochen H M Prehn
Journal:  J Cell Biol       Date:  2010-03-29       Impact factor: 10.539

10.  AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury.

Authors:  Raymond R Russell; Ji Li; David L Coven; Marc Pypaert; Christoph Zechner; Monica Palmeri; Frank J Giordano; James Mu; Morris J Birnbaum; Lawrence H Young
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.